CLLS

Cellectis S.A.

2.00 USD
-0.16 (-7.41%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Cellectis S.A. stock is down -0.99% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 30% of the previous 9 July’s closed higher than June.

About Cellectis S.A.

Cellectis S.A. develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia.